Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric
antigen receptor modified T cells and bispecific antibodies are bringing new treatment …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …

Despite the discoveries of numerous agents including next generation proteasome
inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) …

Patients with multiple myeloma who are refractory to currently available effective therapies
have short expected survival. Modalities harvesting the knowledge of the immune …

Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …